CYP2D6 and chlorpheniramine pharmacokinetics.

被引：0
|
作者：
Yasuda, SU [1 ]
Zannikos, P [1 ]
Young, AE [1 ]
Fried, KM [1 ]
Wainer, JW [1 ]
Woosley, RL [1 ]
机构：
[1] Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20007 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2001年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P7 / P7
页数：1
相关论文
共 50 条
  • [21] Effect of the CYP2D6*10 Genotype on Tolterodine Pharmacokinetics
    Oishi, Masayo
    Chiba, Koji
    Malhotra, Bimal
    Suwa, Toshio
    DRUG METABOLISM AND DISPOSITION, 2010, 38 (09) : 1456 - 1463
  • [22] CYP2D6 polymorphism, tramadol pharmacokinetics and pupillary response
    Ondřej Slanař
    Milan Nobilis
    Jaroslav Květina
    Jeffrey R. Idle
    František Perlík
    European Journal of Clinical Pharmacology, 2006, 62 : 75 - 76
  • [23] CYP2D6 polymorphism, tramadol pharmacokinetics and pupillary response
    Slanar, O
    Nobilis, M
    Kvetina, J
    Idle, JR
    Perlík, F
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (01) : 75 - 76
  • [24] Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine
    Brynne, N
    Dalén, P
    Alván, G
    Bertilsson, L
    Gabrielsson, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (05) : 529 - 539
  • [25] Is CYP2D6 phenotype predictable from CYP2D6 genotype?
    Kiss, Adam Ferenc
    Toth, Katalin
    Juhasz, Cintia
    Temesvari, Manna
    Paulik, Jozsef
    Hirka, Gabor
    Monostory, Katalin
    MICROCHEMICAL JOURNAL, 2018, 136 : 209 - 214
  • [26] PREDICTING THE IMPACT OF CYP2D6/UGT2B7GENE-DRUG AND CYP MEDIATED DRUG-DRUG INTERACTIONS ON OXYCODONE AND OXYMORPHONE PHARMACOKINETICS.
    Silva, C. De Miranda
    Mangal, N.
    Michaud, V.
    Turgeon, J.
    Lesko, L. J.
    Schmidt, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S14 - S14
  • [27] The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype
    Ayman Al-Shurbaji
    Juliette Säwe
    European Journal of Clinical Pharmacology, 2002, 57 : 877 - 881
  • [28] The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype
    Al-Shurbaji, A
    Säwe, J
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 57 (12) : 877 - 881
  • [29] Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6
    Livezey, Mara R.
    Briggs, Erran D.
    Bolles, Amanda K.
    Nagy, Leslie D.
    Fujiwara, Rina
    Furge, Laura Lowe
    XENOBIOTICA, 2014, 44 (04) : 309 - 319
  • [30] Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR
    Hersberger, M
    Marti-Jaun, J
    Rentsch, K
    Hänseler, E
    CLINICAL CHEMISTRY, 2000, 46 (08) : 1072 - 1077
12345